文献速递膀胱癌与上尿路尿路上皮癌

转移性上尿路尿路上皮癌减瘤术后的结局与生存分析

Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma.
PubMed 文献 · Urology · 2021-01-20

基于美国国家癌症数据库2004至2015年接受一线多药化疗的cM1上尿路尿路上皮癌患者,按是否接受减瘤手术分组比较总生存。减瘤手术组中位OS为13.7个月,优于单纯化疗组的10.8个月,倾向评分与逆概率加权调整后减瘤手术仍与显著OS获益相关。

要点

  • 转移性UTUC化疗后行减瘤手术与更长中位OS相关(13.7 vs 10.8个月)。
  • 倾向评分和IPTW调整后减瘤手术的OS获益仍显著。
  • 体能评分、学术机构治疗及减瘤手术是OS的预测因素。

核心结论

  • 对接受全身治疗的M1 UTUC患者,减瘤手术与显著的总生存获益相关。
  • 作者认为需纵向研究评估在可行时手术在多学科治疗中的作用。

研究设计与样本

  • 回顾性队列研究,数据来自美国国家癌症数据库(National Cancer Database)。
  • 按Charlson-Deyo体能评分筛选手术候选者,分为化疗后减瘤手术组与单纯化疗组。
  • 排除接受放疗、免疫治疗或其他类型治疗的患者。
  • 采用Cox比例风险模型、倾向评分匹配及逆概率加权回归比较OS。

主要发现

  • 349例(29.5%)接受了确定性手术。
  • 手术组患者更年轻且更多在学术机构接受治疗。
  • OS预测因素包括体能评分、学术机构治疗及实施减瘤手术。

临床怎么用

  • 对体能状态适合的转移性UTUC患者,在全身化疗后行减瘤手术可作为多学科讨论中的可选策略。
  • 学术机构治疗与更优OS相关,提示诊疗经验与多学科管理可能影响结局。

局限性

  • 为回顾性数据库研究,存在选择偏倚,手术组更年轻且更多在学术机构治疗。
  • 需纵向研究进一步验证手术在罕见转移性UTUC多学科治疗中的角色。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To analyze utilization and outcomes of cytoreductive surgery (CRS) after systemic chemotherapy in select patients with metastatic upper tract urothelial carcinoma (UTUC). MATERIAL AND METHODS: We identified 1,73 patients with cM1 UTUC from the National Cancer Database who were treated with first-line multiagent chemotherapy from 2004 to 2015. Patients considered surgical candidates based on Charlon-Deyo performance score were stratified into nonsurgical versus surgical arms based on receipt of CRS after systemic therapy. Those receiving radiation, immunotherapy, or other types of treatment were excluded. Cox proportional hazard models were used to analyze prognostic factors for overall survival (OS). Propensity-score matching and inverse probability of treatment weighting-adjusted regression models were used to compare OS. RESULTS: A total of 1182 patients were included of which 349 (29.5%) were treated with definitive surgery. Median follow-up was 64 months (95% confidence interval:49.8-79.4) for chemotherapy+surgery versus 61.2 (52.2-78.7) for the chemotherapy-alone arms (P = .09). Patients treated with surgery were younger and more commonly treated at academic facilities. Patients who received CRS had improved median-OS versus those treated with chemotherapy alone (13.7 vs 10.8 months, log-rank P-value <.001). Predictors of OS were performance score, treatment at academic facility, and performance of CRS. Furthermore, in propensity-score and inverse probability of treatment weighting-adjusted Cox regression analyses, CRS was associated with significant OS benefit (hazard ratios = 0.61, 95% confidence interval:0.49-0.77, and 0.63;0.55-0.72; respectively). CONCLUSION: We provide a contemporary report on the survival benefit of CRS after treatment with systemic therapy for M1 UTUC patients. Longitudinal studies are needed to evaluate the role of surgery, when feasible, within multidisciplinary approaches for this relatively, rare disease.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Pollock G, Hsu CH, Batai K, et al. Postoperative and Survival Outcomes After Cytoreductive Surgery in the Treatment of Metastatic Upper Tract Urothelial Carcinoma. Urology. 2021. PMID: 33482133. doi:10.1016/j.urology.2021.01.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。